The cannabinoid receptor 2 is critical for the host response to sepsis

Journal of Immunology

Volumn 183, Issue 1, 2009, Pages 499-505

  Tschöp, Johannes ^a,c   Kasten, Kevin R ^a   Nogueiras, Ruben ^a   Goetzman, Holly S ^a   Cave, Cynthia M ^a   England, Lisa G ^a,b   Dattilo, Jonathan ^a   Lentsch, Alex B ^a   Tschöp, Matthias H ^a   Caldwell, Charles C ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CYCLIC AMP; GP 1A; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; N (PIPERIDIN 1 YL) 1 (2,4 DICHLOROPHENYL) 1,4 DIHYDRO 6 METHYLINDENO[1,2 C]PYRAZOLE 3 CARBOXAMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALPHA2 INTEGRIN; AUTACOID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL COUNT; BLOOD LEVEL; C57BL 6 MOUSE; CECUM; CELL FUNCTION; CELL SUSPENSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE DELETION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LIGATION; LUNG INJURY; LUNG LAVAGE; MALE; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SURVIVAL TIME; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG POTENTIATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MICROBIOLOGY; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; PUNCTURE; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

ANIMALS; BACTEREMIA; CECUM; DISEASE MODELS, ANIMAL; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTEGRIN ALPHA2; LIGATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; PUNCTURES; RECEPTOR, CANNABINOID, CB2; SHOCK, SEPTIC; SIGNAL TRANSDUCTION;

EID: 68949083424     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900203     Document Type: Article

References (36)

1. Klein, T. W., and G. A. Cabral. 2006. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J. Neuroimm. Pharmacol. 1: 50-64.
2. Matsuda, L. A., S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564. (Pubitemid 120005945)
3. Munro, S., K. L. Thomas, and M. Abu-Shaar. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
4. Herkenham, M., A. B. Lynn, M. R. Johnson, L. S. Melvin, B. R. de Costa, and K. C. Rice. 1991. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11: 563-583.
5. Cota, D., G. Marsicano, M. Tschop, Y. Grubler, C. Flachskamm, M. Schubert, D. Auer, A. Yassouridis, C. Thone-Reineke, S. Ortmann, et al. 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112: 423-431.
6. Klein, T. W., C. Newton, and H. Friedman. 1998. Cannabinoid receptors and the cytokine network. Adv. Exp. Med. Biol. 437: 215-222.
7. Howlett, A. C., M. R. Johnson, L. S. Melvin, and G. M. Milne. 1988. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 33: 297-302.
8. Gertsch, J., R. Schoop, U. Kuenzle, and A. Suter. 2004. Echinacea alkylamides modulate TNF-α gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett. 577: 563-569.
9. Devane, W. A., L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
10. Mechoulam, R., S. Ben-Shabat, L. Hanus, M. Ligumsky, N. E. Kaminski, A. R. Schatz, A. Gopher, S. Almog, B. R. Martin, D. R. Compton, et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50: 83-90.
11. Stella, N., P. Schweitzer, and D. Piomelli. 1997. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773-778.
12. Varga, K., J. A. Wagner, D. T. Bridgen, and G. Kunos. 1998. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12: 1035-1044.
13. Oka, S., J. Wakui, M. Gokoh, S. Kishimoto, and T. Sugiura. 2006. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. Eur. J. Pharmacol. 538: 154-162.
14. Facchinetti, F., E. Del Giudice, S. Furegato, M. Passarotto, and A. Leon. 2003. Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Glia 41: 161-168.
15. Gallily, R., A. Breuer, and R. Mechoulam. 2000. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice. Eur. J. Pharmacol. 406: R5-7.
16. Ouyang, Y., S. G. Hwang, S. H. Han, and N. E. Kaminski. 1998. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol. Pharmacol. 53: 676-683. (Pubitemid 28196490)
17. Schwarz, H., F. J. Blanco, and M. Lotz. 1994. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol. 55: 107-115.
18. Gatley, S. J., R. Lan, N. D. Volkow, N. Pappas, P. King, C. T. Wong, A. N. Gifford, B. Pyatt, S. L. Dewey, and A. Makriyannis. 1998. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J. Neurochem. 70: 417-423.
19. Kadoi, Y., H. Hinohara, F. Kunimoto, S. Saito, and F. Goto. 2005. Cannabinoid antagonist AM 281 reduces mortality rate and neurologic dysfunction after cecal ligation and puncture in rats. Crit. Care Med. 33: 2629-2636.
20. Kadoi, Y., H. Hinohara, F. Kunimoto, H. Kuwano, S. Saito, and F. Goto. 2005. Effects of AM281, a cannabinoid antagonist, on systemic haemodynamics, internal carotid artery blood flow and mortality in septic shock in rats. Br. J. Anaesth. 94: 563-568.
21. Kadoi, Y., and F. Goto. 2006. Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine. J Anesth. 20: 284-289.
22. Murineddu, G., P. Lazzari, S. Ruiu, A. Sanna, G. Loriga, I. Manca, M. Falzoi, C. Dessi, M. M. Curzu, G. Chelucci, et al. 2006. Tricyclic pyrazoles, 4: synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2′,4′-dichlorophenyl)-6-methyl-N- piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. J Med Chem. 49: 7502-7512.
23. Chaudry, I. H., H. Hirasawa, and A. E. Baue. 1980. Effect of adenosine triphosphate- glucose administration following sepsis. J. Surg. Res. 29: 348-356.
24. Remick, D. G., G. R. Bolgos, J. Siddiqui, J. Shin, and J. A. Nemzek. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17: 463-467.
25. Goral, J., and E. J. Kovacs. 2005. In vivo ethanol exposure down-regulates TLR2-, TLR4-, and TLR9-mediated macrophage inflammatory response by limiting p38 and ERK1/2 activation. J. Immunol. 174: 456-463. (Pubitemid 40007435)
26. Saeed, R. W., S. Varma, T. Peng, K. J. Tracey, B. Sherry, and C. N. Metz. 2004. Ethanol blocks leukocyte recruitment and endothelial cell activation in vivo and in vitro. J. Immunol. 173: 6376-6383.
27. Ciesla, D. J., E. E. Moore, J. L. Johnson, J. M. Burch, C. C. Cothren, and A. Sauaia. 2005. The role of the lung in postinjury multiple organ failure. Surgery 138: 749-757, discussion 757-748.
28. Gallowitsch-Puerta, M., and K. J. Tracey. 2005. Immunologic role of the cholinergic anti-inflammatory pathway and the nicotinic acetylcholine α 7 receptor. Ann. NY Acad. Sci. 1062: 209-219.
29. Heflin, A. C., Jr., and K. L. Brigham. 1981. Prevention by granulocyte depletion of increased vascular permeability of sheep lung following endotoxemia. J. Clin. Invest. 68: 1253-1260. (Pubitemid 12235026)
30. Ward, P. A., and J. Varani. 1990. Mechanisms of neutrophil-mediated killing of endothelial cells. J. Leukocyte Biol. 48: 97-102.
31. Noronha-Blob, L., V. C. Lowe, L. Otterbein, L. Steranka, and R. M. Burch. 1993. NPC 15669 reduces mortality associated with sepsis in rats. J. Pharmacol. Exp. Ther. 267: 664-669.
32. Hoesel, L. M., T. A. Neff, S. B. Neff, J. G. Younger, E. W. Olle, H. Gao, M. J. Pianko, K. D. Bernacki, J. V. Sarma, and P. A. Ward. 2005. Harmful and protective roles of neutrophils in sepsis. Shock 24: 40-47.
33. Kaufmann, I., G. Schelling, C. Eisner, H. P. Richter, T. Krauseneck, M. Vogeser, D. Hauer, P. Campolongo, A. Chouker, A. Beyer, and M. Thiel. 2008. Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 33: 676-685.
34. Wang, Y., Y. Liu, Y. Ito, T. Hashiguchi, I. Kitajima, M. Yamakuchi, H. Shimizu, S. Matsuo, H. Imaizumi, and I. Maruyama. 2001. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal. Biochem. 294: 73-82.
35. Ydrenius, L., M. Majeed, B. J. Rasmusson, O. Stendahl, and E. Sarndahl. 2000. Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosis. J. Leukocyte Biol. 67: 520-528.
36. Coffey, R. G. 1992. Effects of cyclic nucleotides on granulocytes. Immunol. Ser. 57: 301-338.